Europe’s Drugmakers Turn to AI to Cut Risk and Gain Speed

European drugmakers are using AI to reduce risk and speed R&D, guided by regulators and stronger data governance

4 Feb 2026

Drug development is famously slow and expensive. In Europe it is also becoming more digital. Artificial intelligence is creeping into how medicines are formulated, tested and delivered, nudging an uncertain process towards one guided more by data than by trial and error.

The change is not being led by splashy takeovers or bold claims of automation. Instead it rests on quieter moves: targeted investments, partnerships with technology firms and clearer signals from regulators. Together they suggest that AI is becoming a practical tool in pharmaceutical research, rather than a fashionable add-on.

European drugmakers are applying algorithms to help decide which compounds to pursue, how to design trials and how medicines might best reach patients. The goal is modest but valuable: to cut risk earlier in development and avoid costly failures later on. In an industry where most experimental drugs never reach the market, even small improvements matter.

Regulators have lent cautious support. The European Medicines Agency and others have issued guidance on the responsible use of AI across the drug lifecycle. These papers stop short of endorsing specific systems, but they give firms more confidence to experiment within defined rules on governance, transparency and safety.

Large companies are already adjusting. Roche and Novartis, among others, are using machine-learning tools to speed up drug discovery and improve how data from experiments are analysed. The focus is on screening and prioritisation, not on replacing human judgement. Across the continent, digital teams are being drawn closer to core research functions, reflecting a shift towards more predictive development.

Timing matters. The cost of bringing a new drug to market keeps rising, while pressure grows to deliver treatments faster and tailor them to narrower groups of patients. AI offers a way to balance these demands. By learning from large sets of historical and experimental data, algorithms can help teams rule out weak options sooner. As one industry observer has put it, AI is increasingly seen as a way to manage risk, not to eliminate it.

Obstacles remain. Data are often patchy, and firms must show that AI-backed insights can be explained and trusted. Companies such as AstraZeneca stress the need to keep humans firmly in the loop, using machines to support decisions rather than make them outright.

Even so, the direction is clear. AI is moving beyond pilots and into everyday research workflows. As tools improve and oversight strengthens, Europe’s drug industry hopes for smarter design, faster development and, eventually, better medicines.